Search
Flucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … by Merck in 2019).
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalThe antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation … [L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR
Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243] … [A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension.
Lomitapide
go.drugbank.com/drugs/DB08827Approved[A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity. … Unlike traditional statin therapy, which relies on the upregulation of LDL receptors to clear cholesterol, Lomitapide acts independently of the LDL receptor by preventing the assembly and secretion of
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaSynonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDEEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients. … [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system.
Potassium hydroxide
go.drugbank.com/drugs/DB11153Approved[L1946,L1951] This ingredient has been considered as generally safe as a direct human food ingredient by the FDA, based upon the observance of several good manufacturing practice conditions of use. … Potassium hydroxide is also a precursor to other potassium compounds. Potassium hydroxide is used in food to adjust pH, as a stabilizer, and as a thickening agent.
Mixtures: Vamin NViltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalViltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526] … Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function
Avacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigational[A260801] Avacincaptag pegol was approved by the FDA on August 4, 2023, under the brand name IZERVAY for the treatment of GA secondary to AMD. … [A260801] Although anti-VEGF therapy is available for the neovascular form of AMD, no treatment was approved for GA.